Table 4

Arginine-induced maximal secretion test

InterventionPLA+NaClPLA+GIPPLA+GLP-1SU+NaClSU+GIPSU+GLP-1Interaction P value
C-peptide
HNF1A mutation carriers
  Peak (nmol/L)1.2 ± 0.11.4 ± 0.21.8 ± 0.2*‡1.8 ± 0.22.2 ± 0.3*†‡2.5 ± 0.3*†‡§0.1963
  AUC120–125 min (nmol/L × min)4.9 ± 0.45.4 ± 0.77.0 ± 0.7*6.8 ± 0.89.3 ± 1.1*†‡10.0 ± 1.0*†‡§0.1193
  iAUC120–125 min (nmol/L × min)2.2 ± 0.32.1 ± 0.42.8 ± 0.43.1 ± 0.43.2 ± 0.53.9 ± 0.6‡0.9680
 Control subjects without diabetes
  Peak (nmol/L)2.2 ± 0.23.0 ± 0.33.4 ± 0.4*2.9 ± 0.43.7 ± 0.55.0 ± 0.6*†‡§0.1801
  AUC120–125 min (nmol/L × min)8.3 ± 0.912.3 ± 1.114.1 ± 1.7*11.8 ± 1.716.1 ± 2.1*22.0 ± 2.6*†‡§0.1385
  iAUC120–125 min (nmol/L × min)4.8 ± 0.65.3 ± 0.75.7 ± 0.65.8 ± 0.95.9 ± 0.96.9 ± 1.00.8340
Glucagon
HNF1A mutation carriers
  Peak (nmol/L)41 ± 544 ± 436 ± 432 ± 435 ± 334 ± 40.1797
  AUC120–125 min (nmol/L × min)508 ± 71428 ± 88293 ± 52414 ± 69467 ± 89356 ± 550.2300
  iAUC120–125 min (nmol/L × min)128 ± 16129 ± 13104 ± 1595 ± 17112 ± 11109 ± 170.2671
 Control subjects without diabetes
  Peak (nmol/L)30 ± 431 ± 325 ± 324 ± 326 ± 320 ± 3†0.9993
  AUC120–125 min (nmol/L × min)287 ± 50256 ± 41160 ± 39*237 ± 41217 ± 32212 ± 540.2801
  iAUC120–125 min (nmol/L × min)99 ± 1497 ± 1373 ± 1678 ± 1579 ± 1279 ± 150.5468
  • Data are mean ± SEM. iAUC120–125 min is the incremental values from time 120 min, when 5 g arginine was given as a bolus.

  • PLA, placebo.

  • Symbols show significant differences (P < 0.05) between interventions:

  • * significantly greater than PLA+NaCl;

  • significantly greater SU+NaCl;

  • significantly greater than PLA+GIP;

  • § significantly greater than PLA+GLP-1.